“The present problem has exposed some structural weaknesses inside the EU’s medicines provide chain in addition to a higher dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides reported. She suggested that supply chain troubles be resolved within an EU pharmaceutical system envisioned to become launc